contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


annexin-pharmaceuticals-ab-biostock-annexins-phase-ii-study-fully-recruited-with-positive-signals

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Annexin Pharmaceuticals

Annexin Pharmaceuticals has announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated...

<div class="abstract"><p>Annexin Pharmaceuticals has announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated, and the results so far show a favorable safety profile and promising efficacy signals. The company is expected to present top-line data during the summer of 2024.</p></div><p>Read the article about Annexin Pharmaceuticals&nbsp;here:</p><p><a href="https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/&nbsp;(https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/)">https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/&nbsp;(https://www.biostock.se/en/2024/04/annexins-phase-ii-study-fully-recruited-with-positive-signals/)</a></p><p>This is a press release from&nbsp;BioStock - Connecting Innovation &amp; Capital.&nbsp;<a href="https://www.biostock.se/">https://www.biostock.se/</a></p>

Annexin Pharmaceuticals AB: BioStock: Annexin's phase II study fully recruited with positive signals

Talouden myyttejä murtamassa: Saksan teollisuus on menneen talven lumia

Federal Reserven korkopäätös: Riidankylväjät vauhdissa

Taloustieteen myyttejä murtamassa: Datakeskusinvestoinnit johtavat aina vain parempaan tekoälyyn

EKP:n korkopäätös: Tulkoon joulu (..ja talousoptimismi)

Nousuviikko takana, USA:n työllisyystaantuma ei edelleenkään luvuissa